Clinical trialNCT00687908CompletedPhase 3Interventional

Adapalene-Benzoy Peroxide (BPO) Gel in the Treatment of Acne Vulgaris as a 6-month Maintenance

SponsorGalderma R&DEnrollment243Acne

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to demonstrate the efficacy of Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel compared to its Vehicle Gel as an acne maintenance treatment in Subjects previously treated with Adapalene-BPO Gel or Adapalene-BPO Vehicle Gel both associated with Doxycycline Hyclate 100 mg. The safety of the two investigational treatments will also be assessed.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Diane Thiboutot, MD
Penn State College of Medicine, Hershey, PA
Principal InvestigatorKOL profile →
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

33 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada

Galderma Investigational Site
Barrie, Ontario, Canada
Galderma Investigational Site
North Bay, Ontario, Canada
Galderma Investigational Site
Windsor, Ontario, Canada
Galderma Investigational Site
Québec, Quebec, Canada

Puerto Rico

Galderma Investigational Site
Aibonito, Puerto Rico
Galderma Investigational Site
Carolina, Puerto Rico

United States

Galderma Investigational Site
San Diego, California, United States
Galderma Investigational Site
Denver, Colorado, United States
Galderma Investigational Site
Longmont, Colorado, United States
Galderma Investigational Site
Miami, Florida, United States
Galderma Investigational Site
Snellville, Georgia, United States
Galderma Investigational Site
Chicago, Illinois, United States
Galderma Investigational Site
Evansville, Indiana, United States
Galderma Investigational Site
Overland Park, Kansas, United States
Galderma Investigational Site
Louisville, Kentucky, United States
Galderma Investigational Site
Detroit, Michigan, United States
Galderma Investigational Site
Fort Gratiot, Michigan, United States
Galderma Investigational Site
Fridley, Minnesota, United States
Galderma Investigational Site
Omaha, Nebraska, United States
Galderma Investigational Site
Albuquerque, New Mexico, United States
Galderma Investigational Site
Stony Brook, New York, United States
Galderma Investigational Site
Winston-Salem, North Carolina, United States
Galderma Investigational Site
Warren, Ohio, United States
Galderma Investigational Site
Hazleton, Pennsylvania, United States
Galderma Investigational Site
Hershey, Pennsylvania, United States
Galderma Investigational Site
Simpsonville, South Carolina, United States
Galderma Investigational Site
Arlington, Texas, United States
Galderma Investigational Site
Austin, Texas, United States
Galderma Investigational Site
College Station, Texas, United States
Galderma Investigational Site
Houston, Texas, United States
Galderma Investigational Site
Lubbock, Texas, United States
Galderma Investigational Site
San Antonio, Texas, United States
Galderma Investigational Site
Webster, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Adapalene 0.1% / Benzoyl Peroxide 2.5% GelVehicle Gel

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 30 Nov 2008
Primary completion: 31 Jul 2009
Completion: 31 Jul 2009
Last update posted: 18 Feb 2021
Registered enrollment: 243
Registry id: NCT00687908

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.